✦ LIBER ✦

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy

✍ Scribed by Shigeru Yutani; Akira Yamada; Kazumi Yoshida; Yukari Takao; Mayumi Tamura; Nobukazu Komatsu; Tatsuya Ide; Masatoshi Tanaka; Michio Sata; Kyogo Itoh

Book ID: 116960005
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 490 KB
Volume: 25
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2007.08.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of low-dose intermittent interf

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy

✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec

Phase I clinical study of a peptide vacc

Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles

✍ Shigeru Yutani; Nobukazu Komatsu; Shigeki Shichijo; Kazumi Yoshida; Hiroko Taked 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 840 KB